Mission Bay Capital, the venture capital arm of California Institute for Quantitative Biosciences, helped the replacement therapy developer close its series B round.

Long-term investor Boston Scientific is paying $295m upfront for the 73% of the ablation technology developer it does not own.

LinkedIn's data streaming spinoff, Confluent, is floating above its range in an offering effectively doubling the valuation of its last funding round to over $9bn.

PayPal and Visa have backed Blockchain Capital’s fifth flagship fund, which received $300m of commitments and which will focus on blockchain technology and cryptocurrencies.

Sanofi Ventures co-led replacement therapy developer Glycomine's latest round, which included Novo, Asahi Kasei Pharma Ventures and Chiesi Ventures.

Alexandria Venture Investments backed precision immunology therapeutics developer ImmuneID in the round, which was led by venture capital firm Alta Partners.

Boston Scientific has acquired all remaining shares in its portfolio company Farapulse, having first invested in the University of Iowa spinout in 2014.

Eli Lilly, Johnson & Johnson and Pfizer helped drug developer TRexBio close its $59m series A round while Slack backed human resources software provider Oyster at a $475m valuation.

HubSpot and Salesforce both participated in a series D round which boosted the enterprise software marketplace's overall funding to $257m.

Bloomberg Beta invested in a round which will fund Primer's NLP product development for the government and commercial sectors.